Online citations, reference lists, and bibliographies.

Therapeutic Radionuclides: Production, Physical Characteristics, And Applications

Suresh Chandra Srivastava, Leonard F. Mausner
Published 2013 · Computer Science

Cite This
Download PDF
Analyze on Scholarcy
Share
This chapter will focus primarily on the selection criteria, production, and the nuclear, physical, and chemical properties of therapeutic radionuclides, including those that are currently being used, or studied and evaluated, and those that warrant future investigations. Various scientific and practical issues related to the production and availability of these radionuclides will also be addressed. It is expected that this chapter will form the basis for the other chapters in this volume that will in much greater detail deal with radiopharmaceuticals based on a number of these therapeutic radionuclides and their present and potential usefulness in the clinical setting for treating cancer and other disorders. We are also reintroducing and reinforcing our recently proposed paradigm that involves specific individual “dual-purpose” radionuclides or radionuclide pairs with emissions suitable for both imaging and therapy, and which when molecularly (selectively) targeted using appropriate carriers, would allow pre-therapy low-dose imaging plus higher dose therapy in the same patient. We have made an attempt to sort out and organize a number of such theragnostic radionuclides and radionuclide pairs that may thus potentially bring us closer to the age-long dream of personalized medicine for performing tailored low-dose molecular imaging (SPECT/CT or PET/CT) to provide the necessary pre-therapy information on biodistribution, dosimetry, the limiting or critical organ or tissue, and the maximum tolerated dose (MTD), etc., followed by performing higher dose targeted molecular therapy in the same patient with the same radiopharmaceutical. Beginning in the 1980s, our work at Brookhaven National Laboratory (BNL) with such a “dual-purpose” radionuclide, tin-117m, convinced us that it is arguably one of the most promising theragnostic radionuclides and we have continued to concentrate on this effort. Our results with this radionuclide are therefore covered in somewhat greater detail in this chapter. A major problem that continues to be addressed but remains yet to be fully resolved is the lack of availability, in sufficient quantities and at reasonable cost, of a majority of the best candidate radionuclides in a no-carrier-added (NCA) form. A brief description is provided of the recently developed new or modified methods at BNL for the production of five theragnostic radionuclide/radionuclide pair items, as well as some other therapeutic radionuclides which have become commercially available, whose nuclear, physical, and chemical characteristics seem to show promise for therapeutic oncology and for treating other disorders that respond to radionuclide therapy.
This paper references
10.1016/0020-708X(79)90093-0
Cyclotron production of carrier-free cobalt-55, a new positron-emitting label for bleomycin
M. Lagunas-Solar (1979)
Tyr(3) octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model
J P Norenberg (2006)
10.1021/AC0580114
Production of Ac-225 from Th-229 for targeted alpha therapy.
C. Apostolidis (2005)
Production and investigation of the
G Kadina (1990)
Scandium 47: a replacement for Cu-67 in nuclear medicine therapy with beta/gamma emitters. In: Stevenson N (ed) Isotope production and applications in the twenty first Century
LF Mausner (2000)
Technetium and rhenium in chemistry and nuclear medicine
M. Nicolini (1990)
10.1007/978-94-009-1768-2_4
Therapeutic radionuclides: Making the right choice
S. C. Srivastava (1996)
Theragnostic’’ radiopharmaceuticals: the ‘Janus’ approach to molecular diagnosis and therapy. CME session # 63 on novel radiopharmaceuticals for molecular imaging and therapy—where are we headed next
SC Srivastava (2009)
1997a) Burn-up crosssection of W-188
S Mirzadeh (1997)
Approaches to labeling of antibodies for diagnosis and therapy of cancer
AR Fritzberg (1988)
Macrocyclic polyaminocarboxylates for radiometal antibody conjugates for therapy, SPECT and PET imaging
RC Mease (1997)
Enhanced retention of the alpha-particle-emitting daughters of Actinium-225 by liposome carriers.
Stavroula Sofou (2007)
Meinken GE (2012b) Method of electroplating a conversion electron emitting source on implant
SC Srivastava (2011)
Radioimmunotherapy of human colon carcinoma by I-131 labeled monoclonal antibodies in a mouse model
F Buchegger (1988)
10.1080/10256018608623698
Comparative Studies on the Development of a 188W-188Re Generator
N. Botros (1986)
10.1118/1.595559
Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies.
B. Wessels (1984)
Bohr N (1936) Neutron capture and nuclear constitution
A metallofullerene that
K Akiyama (2009)
Production of 70-day tungsten-188 and development of a 17 hour rhenium-188 radioisotope generator
RE Lewis (1966)
High-Level Production of α-Particle–Emitting 211At and Preparation of 211At-Labeled Antibodies for Clinical Use
M. Zalutsky (2001)
10.1016/0360-3016(90)90467-X
Radiobiological aspects of low dose rates in radioimmunotherapy.
J. Fowler (1990)
10.1016/0883-2897(91)90063-Q
Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates.
O. Gansow (1991)
10.1016/S0969-8043(98)00016-5
Radiochemical purification of no-carrier-added scandium-47 for radioimmunotherapy.
K. Kolsky (1998)
Treatment of metastatic bone pain with tin-117m(4+)DTPA: a phase II clinical study
SC Srivastava (1998)
Processing of reactor-produced Tungsten-188 for fabrication of clinical scale alumina-based Tungsten-188/Rhenium-188 generators
FF JrKnapp (1994)
Tungstate-ionalumina interaction in a 188W/188Re biomedical generator
E Dadachova (1995)
Cyclotron processing of carrier-free 111In
LC Brown (1972)
10.1524/ract.1997.77.12.103
Radionuclide Generators
R. Lambrecht (1997)
10.1016/S0969-8043(96)00284-9
Evaluation of neutron inelastic scattering for radioisotope production
S. Mirzadeh (1997)
10.1007/S10967-005-0623-Y
Production of high specific activity 68Ge at Brookhaven National Laboratory
G. Meinken (2005)
Intravascular stents electroplated with Sn reduce arterial wall inflammation in hyperlipidemic rabbits
J Li (2008)
Potential use of alpha emitting radionuclides in the treatment of cancer
DS Wilbur (1990)
Elementary introduction to reactor physics
S E Liverhaut (1960)
Dosimetric measurements and radiobiological consequences of radioimmunotherapy in mice
B W Wessels (1985)
10.1016/0969-8043(94)00149-T
[166Dy]dysprosium/[166Ho]holmium in vivo generator.
S. Smith (1995)
10.1002/ijc.2910410123
Radioimmunotherapy of human colon carcinoma by 131I‐labelled monoclonal anti‐cea antibodies in a nude mouse model
F. Buchegger (1988)
10.1016/0020-708X(71)90082-2
Chemical processing of cyclotron- produced 67Ga
L. C. Brown (1971)
10.1016/J.APRADISO.2004.12.003
Production of actinium-225 for alpha particle mediated radioimmunotherapy.
R. Boll (2005)
Production of nocarrier-added Sn-117m at medium energy cyclotrons
B Zhuikov (2012)
10.3769/radioisotopes.44.151
Recent Development of 188W-188Re Generator for Biomedical Applications.
Hiroshi Kamioki (1995)
Status on the compilation of nuclear data for medical radioisotope produced by accelerators
D. Gandarias-Cruz (1988)
Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy.
M. H. Griffith (1988)
10.1016/S0001-2998(96)80033-X
Is there life after technetium: what is the potential for developing new broad-based radionuclides?
S. Srivastava (1996)
10.1023/A:1015995208444
Approaches to Radiolabeling of Antibodies for Diagnosis and Therapy of Cancer
A. Fritzberg (1988)
10.1053/j.semnuclmed.2011.12.004
Paving the way to personalized medicine: production of some promising theragnostic radionuclides at Brookhaven National Laboratory.
Suresh Chandra Srivastava (2012)
10.1016/0883-2889(92)90053-H
Improved specific activity of reactor produced 117mSn with the Szilard-Chalmers process
Leonard F. Mausner (1992)
Theragnostic radiometals: getting closer to personalized medicine. In: Mazzi U et al (eds) Technetium and other radiometals in chemistry and nuclear medicine
SC Srivastava (2010)
Adjuvant radioimmunotherapy for micrometastases. In: Srivastava SC (ed) Radiolabeled monoclonal antibodies for imaging and therapy, Plenum
RE Bigler (1988)
A metallofullerene that encapsulates Ac-225
K Akiyama (2009)
10.1016/0020-708X(69)90138-0
Un générateur de 188Re à partir de 188W
J. Blachot (1969)
10.1016/j.addr.2008.04.009
Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.
M. Miederer (2008)
10.1016/0375-9474(69)90686-1
Level and isomer systematics in even tin isotopes from 108Sn to 118Sn observed in Cd(α, xn) reactions
T. Yamazaki (1969)
10.1038/137351a0
Neutron Capture and Nuclear Constitution
(1936)
Intravascular stents electroplated with 117m Sn reduce arterial wall inflammation in hyperlipidemic rabbits
J Li
Improvements in or relating to production of radioactive Iodine -131
CC Evans (1956)
10.1080/09553009014551401
The radiobiology of targeted radiotherapy.
T. Wheldon (1990)
10.1021/j100027a044
Tungstate-Ion-Alumina Interaction in a 188W .fwdarw. 188Re Biomedical Generator
E. Dadachova (1995)
Rhenium-188 for therapeutic applications from an alumina-based tungsten-188/rhenium-188 radionuclide generator
A. Callahan (1989)
Evaluation of an internal cyclotron target for the production of At-211 via the Bi-209(alpha,2n)At-211 reaction
RH Larsen (1996)
10.1007/978-1-4684-5538-0_28
The National Institutes of Health Experience with Radiolabeled Monoclonal Antibodies: Lymphoma, Melanoma, and Colon Cancer
Steven M. Larson (1988)
A new separation procedure for 67Cu from proton irradiation of Zn
AK Dasgupta (1991)
Analysis and refinement of the microspace synthesis of the 195mPt-labeled antitumor drug, cis-DDP
JD Hoeschele (1982)
10.1016/0883-2897(90)90007-N
Antibody radiolabeling, problems and promises.
D. Hnatowich (1990)
10.1016/S0969-8051(97)00180-7
In-vivo tissue uptake and retention of Sn-117m(4+)DTPA in a human subject with metastatic bone pain and in normal mice.
F. Swailem (1998)
10.1007/978-1-4684-5538-0_21
Quantitative Pharmacokinetics of Radiolabeled Monoclonal Antibodies for Imaging and Therapy in Patients
G. Denardo (1988)
10.1524/ract.1983.34.12.25
Production of Some Medically Important Short-Lived Neutron-Deficient Radioisotopes of Halogens
S. M. Qaim (1983)
The radiotoxicity of I-125
EW 22368–371 Bradley (1975)
Reactor production of highspecific activity tin-117m for bone pain palliation and bone cancer therapy
S C Srivastava (2004)
Burn-up crosssection of W-188
S Mirzadeh (1997)
The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy.
M. W. Geerlings (1993)
10.1097/00006231-199302000-00009
The feasibility of 225 Ac as a source of α‐particles in radioimmunotherapy
M. W. Geerlings (1993)
10.2174/1874471011104030186
The ARRONAX project.
F. Haddad (2011)
10.1016/0020-708X(72)90002-6
Cyclotron production of carrier-free indium-111
L. C. Brown (1972)
10.1103/RevModPhys.49.1
High-level radioactive waste from light-water reactors
B. Cohen (1977)
10.1007/BF01328970
Biological damage from the Auger effect, possible benefits
L. Feinendegen (1975)
10.1002/jlcr.2580260178
Production of high specific activity 117mSn with the szilard-chalmers process
L. Mausner (1989)
10.1524/ract.1997.77.12.99
Burn-up Cross-Section of 188W
S. Mirzadeh (1997)
10.1158/1078-0432.CCR-05-1264
213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal Model
J. Norenberg (2006)
10.1524/ract.1982.31.12.27
Analysis and Refinement of the Microscale Synthesis of the 195mPt-labeied Antitumor Drug, cis-Dichlorodiammineplatinum(ll), cis-DDP
J. Hoeschele (1982)
10.1016/0020-708X(82)90120-X
Technetium-99m: an historical perspective.
P. Richards (1982)
10.1016/0020-708X(84)90025-5
Radiation absorbed dose estimates at the cellular level for some electron-emitting radionuclides for radioimmunotherapy.
J. A. Jungerman (1984)
Monoclonal antibodies for radiation therapy of melanoma
SJ DeNardo (1982)
10.1016/j.apradiso.2011.10.007
Development of a large scale production of 67Cu from 68Zn at the high energy proton accelerator: closing the 68Zn cycle.
Dmitri G. Medvedev (2012)
Introduction to radioanalytical physics, Nuclear methods monographs No. 1, Elsevier Scientific Publishing Co
G Deconninick (1978)
10.1053/j.semnuclmed.2010.01.002
Cancer therapy with alpha-emitters labeled peptides.
Ekaterina Dadachova (2010)
Dosimetric aspects of radiolabeled antibodies for tumor therapy.
J. Humm (1986)
10.13182/NSE82-A20295
Nuclear Reactor Engineering
A. Robeson (1982)
10.1007/S10967-005-0920-5
Radionuclides used for therapy and suggestion for new candidates
M. Neves (2005)
Rigid bifunctional chelating agents
MP Sweet (2000)
Rhenium-188 generator
Scandium 47 : a replacement for Cu - 67 in nuclear medicine therapy with beta / gamma emitters
LF Mausner (2000)
Cyclotron processing of carrier - free 111 In
LC Brown (1972)
10.1007/S10967-009-0520-X
Production of no-carrier-added 117mSn from proton irradiated antimony
S. V. Ermolaev (2009)
10.1016/0020-708X(75)90125-8
Cyclotron production of 123Xe and high purity 123I: A comparison of tellurium targets☆☆☆
M. Guillaume (1975)
10.1016/0883-2889(86)90192-9
Production of no-carrier added 67Cu.
S. Mirzadeh (1986)
10.1089/cbr.1996.11.43
Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy.
S. Srivastava (1996)
10.4103/1450-1147.89779
Improved Quality of Life in Patients Treated with Peptide Radionuclides
T. Traub-Weidinger (2011)
10.1134/S1066362211010103
Production of 225Ac and 223Ra by irradiation of Th with accelerated protons
B. L. Zhuikov (2011)
Improved 188W/188Re zirconiummtungstate. Gel radioisotope generator chemistry
GJ Ehrhardt (1992)
Expression of normal epithelial membrane antigens on human colorectal and breast carcinomas
JW Fabre (1983)
Intravascular Stents Electroplated with Sn-117m reduce arterial wall inflammation in hyperlipemic rabbits
J Li (2007)
Dosimetric measurements and radiobiological consequences of radioimmuno - therapy in mice
BW Wessels (1985)
10.1016/0020-708X(84)90110-8
Production of carrier-free 117mSn
S. M. Qaim (1984)
10.1524/ract.2011.1880
Irradiation of strontium chloride targets at proton energies above 35 MeV to produce PET radioisotope Y-86
D. Medvedev (2011)
10.1007/S10967-005-0091-4
Production of high specific activity 68Ge at Brookhaven National Laboratory
G. Meinken (2005)
The application of linear-quadratic dose-effect to fractionated and protracted radiotherapy
RG Dale (1985)
Theragnostic radiometals : getting closer to personalized medicine
SC Srivastava (2010)
Intravascular Stents Electroplated with Sn-117m reduce arterial wall inflammation in hyperlipemic rabbits. Presented at the GLS 2007 Meeting
J Li
Level and isomer systematics in even tin isotopes from Sn-108 to Sn-118 observed in Cd(a, xn) Sn reactions
T Yamazaki (1969)
Targetry ‘91. Proceeding of the IVth international workshop in targetry and target chemistry
R Weinreich (1992)
Dosimetric measurements and radiobiological consequences of radioimmunotherapy in mice. In: Schlafek-Stelson AT, Watson EE (eds) Fourth international radiopharmaceutical dosimetry
BW Wessels (1985)
10.1016/0167-5087(83)90342-3
Cross-section systematics for nuclide production at a medium energy spallation neutron facility
S. Mirzadeh (1983)
10.1002/0470846380.CH3
Reactor Production of Radionuclides
L. Mausner (2005)
10.1097/00006231-199104000-00004
Radiolabelled monoclonal antibodies in oncology. III. Radioimmunotherapy.
K. Britton (1991)
10.1016/0883-2897(91)90090-8
Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: a predictive model based on mouse pharmacokinetics.
E. Yorke (1991)
10.1016/j.apradiso.2010.07.022
Evaluation of excitation functions of 3He- and α-particle induced reactions on antimony isotopes with special relevance to the production of iodine-124.
Muhammad Aslam (2011)
High level production of alpha-particle emitting At-211-labreled antibodies for clinical use
MR Zalutsky (2001)
Tumor therapy with radionuclides: assessment of progress and problems
J Carlsson (2003)
10.1259/0007-1285-58-690-515
The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy.
R. Dale (1985)
Kinetic and catabolic considerations of monoclonal antibody targeting in erythroleukemic mice.
D. Scheinberg (1983)
10.1053/SNUC.2001.27043
Recent advances in radionuclide therapy.
S. Srivastava (2001)
10.1080/00337578608208354
Nuclear data for production of 117mSn for biomedical application
L. Mausner (1986)
10.1021/IE990582X
Thermoseparation of neutron-irradiated tungsten from Re and Os
S. Mirzadeh (2000)
10.1524/ract.2011.1869
Chemical and biological evaluation of scandium(III)-polyaminopolycarboxylate complexes as potential PET agents and radiopharmaceuticals
S. Huclier-Markai (2011)
10.1524/ract.2011.1882
Paving the way to personalized medicine: production of some theragnostic radionuclides at Brookhaven National Laboratory
Suresh Chandra Srivastava (2011)
Production of radioactive phosphorous
CC Evans (1957)
Reactor production of high - specific activity tin - 117 m for bone pain palliation and bone cancer therapy
SC Srivastava (2004)
Production and Evaluation of Sc-47 for Radioimmunotherapy
Marco Chinol (1992)
Development and evaluation of tin- 117m labeled Annexin for the imaging and treatment of vulnerable plaques
SC Srivastava (2012)
Radionuclide therapy with high-LET electron emitters: therapeutic applications of conversion electron emitter tin-117m
SC Srivastava (2006)
Status on the compilation of nuclear data for medical radioisotopes produced by accelerators, IAEA Report
D Gandarias-Cruz (1988)
10.1016/S0167-8140(02)00374-2
Tumour therapy with radionuclides: assessment of progress and problems.
J. Carlsson (2003)
Adjuvant radioimmunotherapy for micrometastases
RE Bigler (1988)
The phenotypic heterogeneity of human ovarian tumor cells in relation to cell
RN Buick (1983)
Rigid bifunctional chelating agents. US Patent # 6,022
M P Sweet
10.1158/1078-0432.CCR-07-4647
Preclinical Evaluation of the α-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors
M. Miederer (2008)
10.1016/0029-5582(56)90084-0
Neutron cross sections
S. Mughabghab (1981)
10.1016/0969-8043(93)90172-7
EXCITATION FUNCTIONS OF PROTON INDUCED NUCLEAR REACTIONS ON ENRICHED 61NI AND 64NI : POSSIBILITY OF PRODUCTION OF NO-CARRIER-ADDED 61CU AND 64CU AT A SMALL CYCLOTRON
F. Szélecsényi (1993)
10.1118/1.597045
Selection of radionuclides for radioimmunotherapy.
L. Mausner (1993)
10.1016/0883-2897(87)90038-9
Radiobiologic implications of the microscopic distribution of energy from radionuclides.
S. Adelstein (1987)
10.1007/978-1-4684-5538-0
Radiolabeled Monoclonal Antibodies for Imaging and Therapy
Therapy Potential Problems (1988)
Neutron crosssections
SF Mughabgab (1984)
Sesonske A (1963) Nuclear reactor engineering
S Glasstone (1963)
Production of carrier free 32P
RS Mani (1966)
10.1021/BC070075T
Enhanced Retention of the α-Particle-Emitting Daughters of Actinium-225 by Liposome Carriers
Stavroula Sofou (2007)
10.1016/0047-0740(85)90024-5
The development and in-vivo behavior of tin containing radiopharmaceuticals--II. Autoradiographic and scintigraphic studies in normal animals and in animal models of bone disease.
Z. Oster (1985)
10.2967/JNUMED.109.069948
MIRD: Radionuclide Data and Decay Schemes
Franklin C. Wong (2009)
10.1007/BF02162474
Separation of carrier-free166Ho from Dy2O3 targets by partition chromatography and electrophoresis
E. Dadachova (1995)
10.1016/0883-2897(91)90029-K
Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies.
S. Srivastava (1991)
10.1016/S0969-8043(97)00287-X
Numerical evaluation of the production of radionuclides in a nuclear reactor (Part II).
Saeed Mirzadeh (1998)
Un Generateur de Re-188 a Partir de W-188
J Balchot (1969)
Alpha-particle immunotherapy for acute myeloid leukemia (AML) with bismuth213 and actinium-225
JG Jurcic (2006)
Optimal radionuclideantibody combinations for clinical radioimmunotherapy: A predictive model based on mouse pharmacokinetics
ED Yorke (1991)
Intravascular stents electroplated with 117 mSn reduce arterial wall inflammation in hyperlipidemic rabbits
J Li (2008)
10.1016/j.apradiso.2008.11.012
Cyclotron and linac production of Ac-225.
G. Melville (2009)
10.1021/ac00095a024
Separation of carrier-free Holmium-166 from neutron-irradiated dysprosium targets
E. Dadachova (1994)
10.2307/3574245
The radiotoxicity of iodine-125 in mammalian cells. I. Effects on the survival curve of radioiodine incorporated into DNA.
E. Bradley (1975)
10.2307/3574422
Radiotoxicity of iodine-125 in mammalian cells. II. A comparative study on cell survival and cytogenetic responses to /sup 125/IUdR, /sup 131/IUdR, and /sup 3/HTdR
P. Chan (1976)
10.1016/0883-2889(91)90140-V
A new separation procedure for 67Cu from proton irradiated Zn
A. Dasgupta (1991)
10.1182/BLOOD.V100.4.1233.H81602001233_1233_1239
Targeted α particle immunotherapy for myeloid leukemia
J. Jurcic (2002)
A convenient tungsten-188/rhenium-188 generator for radiotherapeutic applications using low specific activity Tungsten-188
GJ Ehrhardt (1990)
10.1016/0020-708X(83)90073-X
Development and use of the 195mHg-195mAu generator for first pass radionuclide angiography of the heart.
R. Bett (1983)
Production of actinium-225
RA Boll (2005)
Chemical and biological evaluation of scandium (III)-polyamino-polycarboxylate complexes as potential PET agent and radiopharmaceutical
S Huclier-Markai (2011)
The phenotypic heterogeneity of human ovarian tumor cells in relation to cell function
R N Buick (1983)
Production of no- carrier-added Tin-117m from proton irradiated antimony
SV Ermolaev (2009)
Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
G. Denardo (1998)
Alpha-Particle Immunotherapy for Acute Myeloid Leukemia (AML) with Bismuth-213 (213Bi) and Actinium-225 (225Ac)
J. Jurcic (2013)
10.2307/3575714
Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells.
A. I. Kassis (1982)
10.1016/S0969-8043(96)00269-2
Radiolabeling antibodies with holmium-166.
E. Dadachova (1997)
The radiotoxicity of I-125 in mammalian cells. II. A comparative study on cell survival and cytotoxic responses to IUDR-125, and HTdR-3
PC Chan (1976)
Comparative studies on the development of W-188/Re-188 generator
N Botros (1986)
Separation of carrier-free holmium-166 from neutronirradiated dysprosium targets
E Dadachova (1994)
Burn - up cross - section of W - 188
S Mirzadeh
10.1007/s10967-009-0522-8
A metallofullerene that encapsulates 225Ac
K. Akiyama (2009)
Partir de W-188
R Bett (1983)
10.1240/SAV_GBM_2008_M_002137
Transcriptional control by the Polycomb system
Jürg Müller (2008)
10.1007/174_2012_669
Rhenium-188 Generator-Based Radiopharmaceuticals for Therapy
F. F. Knapp (2012)
67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.
S. Denardo (1999)
10.1002/0470846380.CH1
Production of Radionuclides in Accelerators
D. Schlyer (2005)
An improved tungsten-188/rhenium-188 generator for radiotherapeutic applications
G Ehrhardt (1987)
Evaluation of tin-117m labeled Annexin V for imaging atherosclerotic lesions in a hyperlipidemic rabbit model
J Narula (2012)
Re - 188 generator
V Mikheev (1972)
New York Mausner LF (1999) Radiochemical laboratory. In: McGraw Hill encyclopedia of science & technology, 9th edn
A E Martell (1974)
Production and purification of radionuclides
HB Hupf (1976)
An Ac-225/Bi-213 generator system for therapeutic clinical applications: construction and operation
MR McDevitt (1999)
Development of large scale production of Cu-67 from Zn-68 at the high energy accelerator: closing the Zn-68 cycle
DJ Medvedev (2012)
Production of nocarrier-added Cu-67
S Mirzadeh (1986)
10.1016/0969-8043(94)90026-4
Processing of reactor-produced 188W for fabrication of clinical scale alumina-based 188W/188Re generators
F. F. Knapp (1994)
Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides.
J. O'Donoghue (1995)
Therapeutic radionuclides: production and decay property considerations.
W. Volkert (1991)
10.1016/0969-8043(95)00285-5
Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (α,2n)211At reaction
R. Larsen (1996)
Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics.
H. Herzog (1993)
10.1016/S0969-8043(98)00151-1
An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation.
M. McDevitt (1999)
10.1016/j.apradiso.2008.08.017
Radiochemical studies relevant to 86Y production via 86Sr(p,n)86Y for PET imaging.
M. Sadeghi (2009)
10.1016/s0969-8043(97)00287-x
Numerical evaluation of the production of radionuclides in a nuclear reactor (Part I).
S. Mirzadeh (1998)
Cyclotron and short-lived halogen isotopes for radiopharmaceutical applications
R. Lambrecht (1973)



This paper is referenced by
10.1007/s12149-019-01329-w
An assessment of bone-seeking radionuclides for palliation of metastatic bone pain in a vertebral model
Alireza Sadremomtaz (2019)
Microparticules à base d’amidon (SBMP) comme agent théranostique unique pour la radiothérapie sélective interne des tumeurs hépatiques : radiomarquage au gallium-68 et rhénium-188 et étude préliminaire in vivo
E. Verger (2016)
10.1016/J.NIMB.2017.03.037
Computer simulation and experimental investigation of Mo-99 yield in thick targets as a Tc-99m generator
T M Malykhina (2017)
10.1093/annonc/mdz401
Industry corner: perspectives and controversies.
S. Abdullah (2019)
10.1016/B978-0-323-48063-5.00001-0
Nanotechnologies for early diagnosis, in situ disease monitoring, and prevention
Tsai-Jung Wu (2018)
10.1007/978-3-319-63067-0_26
Radiopharmaceuticals for Bone Metastases
Benedetta Pagano (2018)
Fluorescent nanodiamond for tracking the engraftment and repair of lung stem cells
Tsai-Jung Wu ()
10.1088/2399-6528/ab51c9
The study of alpha particle induced reactions on bismuth-209 isotopes using computer code COMPLET
Yihunie Hibstie Asres (2019)
10.1186/s12951-019-0524-9
Current outlook on radionuclide delivery systems: from design consideration to translation into clinics
Oleksii O. Peltek (2019)
10.1080/03639045.2016.1234484
Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part I: purification of decayed thorium-227 on cation exchange columns
Janne Olsen Frenvik (2017)
10.1080/03639045.2017.1318906
Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part II: purification of targeted thorium conjugates on cation exchange columns
Janne Olsen Frenvik (2017)
10.3390/molecules24020334
Perspectives on the Use of Liquid Extraction for Radioisotope Purification
Petra Martini (2019)
10.1186/s13550-019-0515-8
Photonuclear production, chemistry, and in vitro evaluation of the theranostic radionuclide 47Sc
Christopher S Loveless (2019)
10.1016/J.PHYSREP.2019.01.004
Applied nuclear physics at the new high-energy particle accelerator facilities
M. Durante (2019)
10.1021/acs.inorgchem.9b01277
Implementing f-Block Metal Ions in Medicine: Tuning the Size Selectivity of Expanded Macrocycles.
Nikki A Thiele (2019)
Semantic Scholar Logo Some data provided by SemanticScholar